Cross-Species Links: Developmental Origins of Adult Hypersomnia
A new cross‑species study uncovers how early developmental disruptions predispose adults to hypersomnia. Researchers compared mouse, zebrafish, and human data, linking altered orexin signaling and circadian gene expression to chronic sleepiness. The analysis identified three molecular pathways—neuroinflammation, synaptic pruning deficits, and mitochondrial dysfunction—as common drivers. Findings suggest potential biomarkers and therapeutic targets for treating adult hypersomnia across species.
Arguing for Sirtuins to Be Involved in Known Interventions to Modestly Slow Vascular Calcification
Vascular calcification, a hallmark of cardiovascular aging, lacks effective reversal therapies beyond modest chelation. A new open‑access study links the SIRT family of proteins to slowed calcification by modulating inflammation, oxidative stress, and ferroptosis, primarily through metformin‑driven activation of SIRT1...
Gut Dysbiosis Links to Skin Immune Responses in Mice
A recent pre‑clinical study demonstrates that gut dysbiosis in mice drives pronounced skin immune responses, particularly elevating Th17‑mediated inflammation. Researchers induced microbiome imbalance through antibiotics and high‑fat diet, then observed increased skin cytokine levels and histological signs of dermatitis. Fecal...
High-Speed AFM Imaging Reveals How Brain Enzyme Forms a Dodecameric Ring Structure
Scientists at Kanazawa University used high‑speed atomic force microscopy to capture real‑time images of the brain enzyme CaMKII, revealing that its 12‑subunit ring assembles with α and β subunits in a 3:1 ratio. The β subunits preferentially cluster together, forming...
Tjoapack Expands Bottle Packaging at Netherlands Facility
Contract packaging firm Tjoapack announced the addition of an oral solid‑dosage bottle packaging line at its Etten‑Leur, Netherlands site. The Cremer Uhlmann IBC 50 line can fill up to 50 bottles per minute, handling any bottle shape and integrating carton, leaflet and...
Tahoe, Arc Institute, and Biohub Join Forces on Massive Virtual Cell Dataset
Tahoe Therapeutics, the Arc Institute and Biohub have pledged multi‑million‑dollar investments to create the largest virtual‑cell dataset to date, generating more than 120 million single‑cell data points across 225,000 perturbations using Tahoe’s Mosaic technology. The new resource will be over four...
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
The U.S. Food and Drug Administration removed a partial clinical hold on the Phase 3 trial jointly run by Merck and Daiichi Sankyo for a lung‑cancer therapy. The hold, originally imposed over safety and data‑integrity concerns, is now lifted, allowing...
Eye for Trouble: Automated Counting for Chromosome Issues Under the Microscope
Researchers at Tokyo Metropolitan University unveiled a machine‑learning suite that automatically detects and counts sister chromatid exchanges (SCE) in microscope images. The system integrates chromosome identification, SCE classification, and clustering, achieving an overall accuracy of 84.1 %. Validation on cells lacking...
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Eisai announced a licensing agreement with Nuvation Bio to develop a novel lung‑cancer pill, securing exclusive rights and an upfront cash payment plus milestone fees. The deal positions Eisai to expand its oncology portfolio amid competitive immunotherapy markets. Meanwhile, Alnylam...
Jubilant Biosys Announces New Facility in India
Jubilant Biosys Limited announced the opening of a new discovery and pre‑clinical facility in Noida, India, that doubles its chemistry capacity and integrates early‑phase scale‑up with R&D labs. The 20,000‑sq‑ft campus adds fifteen reactors, two pilot‑plant blocks, and expands the...
ABVX's P2b Data Boosts Valuation, Delay Sale
A few serious/non-memey words on $ABVX for the first time in a while. Nobody knows how much of this M&A rumor smoke coming out of France is real. A deal, if any, could be happening soon, or it could take...
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
AbbVie announced a $650 million upfront deal with Chinese biotech RemeGen to acquire a bispecific antibody that simultaneously blocks PD‑1 and VEGF, marking its entry into the fast‑growing PD‑1×VEGF space. The agreement, unveiled at the JPMorgan Healthcare Conference, includes additional milestone...
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
Moderna announced a 2025 revenue outlook of $1.9 billion, aligning with the midpoint of its narrowed $1.6‑$2 billion range and matching Wall Street expectations. The biotech also trimmed its operating expense forecast to $5‑$5.2 billion, a $200 million reduction from the prior November guidance....
Combining IVF and Surgery for Endometriosis Fertility Solutions
A new clinical protocol merges in‑vitro fertilization (IVF) with minimally invasive endometriosis surgery to boost fertility outcomes. Early trials show that removing endometriotic lesions before embryo transfer raises live‑birth rates by up to 25 percent compared with IVF alone. The approach...
JPM: AbbVie Pays $650m Upfront for RemeGen Cancer Drug
AbbVie has signed a $5.6 billion licensing agreement with China’s RemeGen, paying $650 million upfront for exclusive rights to the PD‑1×VEGF bispecific antibody RC148 outside Greater China. The deal includes up to $4.95 billion in milestone payments and gives AbbVie access to a...
Mitigating Emissions From Air Freight: Unlocking the Potential of SAF with Book and Claim
Air freight emissions have jumped 25% since 2019, adding roughly 20 million tonnes of CO₂ annually. Sustainable aviation fuel (SAF) can slash lifecycle greenhouse‑gas emissions by up to 80%, and the IATA sees it delivering 65% of the sector’s reductions. High...
FDA Again Rejects Atara, Pierre Fabre's Cell Therapy for Epstein-Barr Virus
The U.S. Food and Drug Administration has again refused to approve Atara Bio’s EBV‑specific T‑cell therapy, a treatment developed with French partner Pierre Fabre for post‑transplant lymphoproliferative disorder (PTLD). The agency cited insufficient clinical data and unresolved safety concerns, prompting Atara...
Europe’s Cattle Face Rising Future Heatwave Risks
A new climate risk assessment shows that European cattle will face significantly more frequent and intense heatwaves over the next two decades. The study projects a 30‑40% rise in days above 30 °C across major livestock regions, cutting milk yields by...
Breath Analysis Reveals Lipid Biomarkers in Parkinson’s
A recent study demonstrates that exhaled breath analysis can detect distinct lipid biomarkers associated with Parkinson's disease. Researchers collected breath samples from 200 participants spanning early to advanced disease stages and identified a panel of lipids that differentiate patients from...
PD‑1/VEGF Deals Surge, AbbVie Pays $650M Amid
In today's PD-1/VEGF news: $SMMT submitted ivonescimab to the FDA in Q4, as it promised to do, but chose to disclose the filing today... I guess to get a JPM bump? No PDUFA date assigned yet, so.... And $ABBV enters the...
FDA Carves Out Manufacturing Exemptions for CGTs To Accelerate Development
The FDA announced new manufacturing exemptions for cell and gene therapies, allowing developers to bypass certain chemistry, manufacturing and controls (CMC) requirements as products move beyond Phase I. The agency will not enforce Chapter 600 specifications for later‑stage trials and will treat...
Deep Learning Boosts Weed and Rice Detection From UAVs
Researchers have unveiled a deep‑learning system that processes UAV imagery to identify both rice crops and invasive weeds with near‑perfect accuracy. Field trials across Southeast Asian paddies reported detection rates above 96% and a 30% reduction in herbicide applications. The...
Arkin Capital Raises $100M to Back a Dozen Early-Stage Biotechs
Arkin Capital has closed a $100 million third early‑stage biotech fund, aimed at backing 10 to 12 nascent drug‑development companies. The Israel‑based venture firm plans to deploy the capital across a portfolio of early‑stage therapeutics, focusing on innovative platforms and unmet...
ABVX Faces Unofficial $200 Bid Amid Multiple Suitors
$ABVX has an unofficial bid for ~$200/share if you believe the reporting out of France this morning, plus two more potential bidders circling. Of course, the source is reputable enough that the little old Wall Street Journal has picked...
Longevity Clinics Cashing in on Pseudoscience Boom
The big business of longevity pseudoscience and marketing https://t.co/2Os0Q2frQl by @TrishaThadani "The boom in consumer demand has inspired as many as 800 longevity clinics to spring up around the country,... These clinics often charge as much as tens of thousands of...
Abivax Climbs on Lilly Takeover Speculation
Shares of French biotech Abivax jumped about 32% after La Lettre reported that Eli Lilly may be considering a €15 billion takeover. The speculation follows Abivax's positive phase 3 data for obefazimod, an oral miR‑124 enhancer, in ulcerative colitis. The deal would add...
Mitochondrial Transfer Fuels Cancer Spread, Impairs Immunity
The double whammy of mitochondrial transfer from immune cells to cancer cells, reducing immune cel function and powering tumor spread through lymph nodes @Cell_Metabolism https://t.co/q3ZcRObLAc https://t.co/eUAPrxSxlh
Six Essential Bioinformatics Workflow Tools Simplify Analysis
6 links on workflow to make your life easier 🧵 Bioinformatics analysis involves a lot of steps, 6 links on workflow to make your life easier: 1. over hundreds of workflow tools and engines https://t.co/R29TTEYSMB
#JPM26: Moderna CEO Bancel Talks Deals, Flu and RSV Strategy
Moderna CEO Stéphane Bancel told JPMorgan analysts that the company’s deals team has closed several partnership agreements in the first quarter, accelerating its pipeline beyond COVID‑19. He outlined a dual‑track strategy for the upcoming flu season, emphasizing a next‑generation quadrivalent...
Insmed Rides Lung Drug Success, Eyes Next Growth
Insmed $INSM basks in the success of its lung disease drug — and prepares for what’s next. I chatted Sunday with CEO Will Lewis before watching the Patriots beat the Chargers. #JPM26 https://t.co/l56Y7Xw5fS
AI Rebuilt My RNA‑seq Pipeline in Minutes
1/ I wasted hours debugging an RNA-seq pipeline. The next day, I rebuilt it in 45 minutes using Claude Code.
Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s
Novartis is committing $165 million upfront to license a pre‑clinical amyloid‑targeting program from SciNeuro. The partnership will jointly advance the candidate through IND‑enabling studies and later clinical trials. Both companies aim to develop a disease‑modifying Alzheimer’s therapy that can address the...
ATRA Rallies at JPM26, Eyes Upcoming FDA CRL
#JPM26 off to a great start for $ATRA. Looking forward to the FDA publishing the latest CRL.
Moderna Investor Warns US Policy Threatens Vaccine Innovation
Investor behind Moderna $MRNA says U.S. policy is ‘taking a sledgehammer to our miracle machine’ https://t.co/B9MGLzxfZO via @matthewherper #JPM26
Madrigal Eyes Combination MASH Therapy with Pfizer Deal
Madrigal Pharma has licensed Pfizer’s oral DGAT‑2 inhibitor ervogastat for a $50 million upfront payment, planning to pair it with its approved MASH drug Rezdiffra. The combination targets complementary pathways in triglyceride synthesis and inflammation, aiming to enhance therapeutic outcomes for...
Pharma Accelerates PD1‑VEGF Combo Trials Across Major Players
Expect BIG activity from pharma with PD1xVEGF combos… $SMMT Announces Clinical Trial Collaboration with $GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) $PFE has already telegraphed (and started to operationalize) the same playbook. https://t.co/JTY2cuJtMG https://t.co/0zCI8zFouB
Why some “Breakthrough” Technologies Don’t Work Out
MIT Technology Review released its 2026 list of breakthrough technologies, marking the 25th anniversary of the annual roundup. The article revisits past entries that failed—such as Social TV, the Helix DNA app store, universal memory, light‑field photography, and Project Loon—to...
An Opinionated View of Current Issues with Aging Clocks
Aging clocks aim to quantify biological age using molecular data, promising faster assessment of anti‑aging therapies. While dozens of clocks exist, they are currently trusted only for research and personal health monitoring, not for regulatory or clinical decision‑making. The blog...
Living Sensor Display Turns Engineered Skin Into a Biological Monitor
Japanese researchers have engineered a skin graft that lights up in response to inflammation, creating a living sensor display that can be implanted under the skin. The graft uses genetically modified epidermal stem cells that emit green fluorescence when the...
Building More Sustainable Cold Chain Packaging Through Innovation
The pharmaceutical cold‑chain still depends on single‑use expanded polystyrene (EPS) for reliable temperature control, but that reliance generates a massive waste stream and high carbon emissions. Global EPS production exceeds 5 million metric tons annually, yet recycling rates linger below 30 percent,...
5 Questions Facing Biopharma in 2026
The 2026 J.P. Morgan Healthcare Conference highlighted five critical questions for biopharma: whether the 2025 recovery will sustain, if the recent surge in M&A will continue, how the U.S. will counter China’s fast‑growing biotech sector, whether FDA leadership turmoil will...
Best Practices for COA Selection: Building a Stronger Foundation for Clinical Trials
Selecting the right clinical outcome assessment (COA) is now a pivotal determinant of trial success, influencing regulatory acceptance and data relevance. A Pearson Research survey shows 91% of investigators feel under‑prepared, with licensing, translation, and rater training cited as the...
Flagship CEO Calls Out Attacks on Science, Warns of China Dominance
Flagship Pioneering CEO Noubar Afeyan warned that U.S. cuts to NIH, NSF, and BARDA are jeopardizing the country’s biotech “miracle machine.” He highlighted concrete examples such as the resurgence of measles and reduced vaccine recommendations, linking them to policy decisions....
Oncology IPO Outspends AKTS, $800M Funding, $205M R&D
So a nice first day trading for $AKTS, +24%, but here comes an oncology IPO of a quite different order: Eikon has had $800m private money invested in it so far (vs $140m for AKTS), and blew $205m on R&D...
Daidzein From Macrotyloma: Epigenetic Leukemia Therapy
Researchers have identified daidzein, an isoflavone extracted from the legume Macrotyloma, as a potent epigenetic agent against leukemia. In cellular models, daidzein inhibits DNA methyltransferases, leading to demethylation and re‑activation of key tumor‑suppressor genes. Pre‑clinical studies demonstrate selective cytotoxicity toward...
One in Four Older Americans with Dementia Prescribed Risky Brain-Altering Drugs
A new JAMA study finds that about 25% of Medicare beneficiaries with dementia are prescribed potentially inappropriate CNS‑active medications that can cause falls, confusion, and hospitalizations. While overall prescribing of these drugs fell from 20% to 16% among all older...
AI Giants Race Into Healthcare Sector
A few days ago it was @OpenAI, now @Anthropic. The others soon. The push into healthcare https://t.co/5jVJVJ39MH
To Broaden Access to CAR Ts, Mitigate Their Side Effects
The FDA has removed the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved CAR‑T therapies, reflecting confidence in real‑world safety data. Yet only about 30% of eligible patients receive CAR‑T because severe toxicities—cytokine release syndrome (CRS) and immune effector...
Enhanced Tumor Immunotherapy via Targeted Nanoparticles
Researchers have unveiled a targeted nanoparticle platform that dramatically enhances tumor immunotherapy efficacy. The system directs checkpoint‑inhibitor antibodies and cytokines straight to the tumor microenvironment, achieving up to a 300% increase in immune cell infiltration and a 45% reduction in...
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
Eikon Therapeutics, a biotech founded in 2019 by former Merck executives, has raised more than $1 billion and announced plans for an initial public offering. The company’s pipeline includes four clinical candidates, with its lead asset EIK1001 advancing in a Phase 2/3...